EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Novel Dual Inhibitor Targeting Tubulin and Histone Deacetylase 8 for Treatment of the Ovarian Cancer

Shaowen Cai, Furui Shi, Jiayi Chen, Min Yu, Zhixian Shi, Hairong Tang, Yang Wang iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c01002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Shaowen Cai und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Fudan University, Shanghai201203, China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Ovarian Neoplasms, Histone Deacetylases, Tubulin. Die Arbeit nennt 88 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this work, a series of novel dual inhibitors against both tubulin and histone deacetylase (HDAC) were designed and synthesized by integrating the natural product Millepachine with the key pharmacophore of HDAC inhibitors. Among them, compound 6 exhibited potent antiproliferative activity against 12 cancer cell lines, with IC50 values ranging from 0.020 to 0.244 μM. Mechanistic investigations revealed that compound 6 inhibited both tubulin polymerization (IC50 2.0 μM) and HDAC8 (IC50 0.110 μM), with 54-, 27- and 132-fold selectivity over HDAC1, HDAC4 and HDAC6, respectively. In an ovarian cancer xenograft mouse model, compound 6 exhibited significant inhibitory effect on tumor growth with a favorable safety profile. These findings identify compound 6 as a promising tubulin/HDAC8 dual inhibitor for further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsOvarian NeoplasmsHistone DeacetylasesTubulinAntineoplastic AgentsRepressor ProteinsTubulin ModulatorsFemaleHumansAnimalsCell Line, TumorMiceCell ProliferationStructure-Activity RelationshipMice, NudeDrug Screening Assays, AntitumorXenograft Model Antitumor AssaysDrug Discovery

Stichwörter der Autor:innen

HDAC8antitumordual inhibitortubulin

Substanzen

Histone Deacetylase InhibitorsHistone DeacetylasesTubulinAntineoplastic AgentsHDAC8 protein, humanRepressor ProteinsTubulin Modulators

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Fudan University, Shanghai201203, China.

ORCID-Profile: Yang Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cai, S., Shi, F., Chen, J., Yu, M., Shi, Z., Tang, H., & Wang, Y. (2026). Discovery of a Novel Dual Inhibitor Targeting Tubulin and Histone Deacetylase 8 for Treatment of the Ovarian Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01002

Vancouver

Cai S, Shi F, Chen J, Yu M, Shi Z, Tang H, et al. Discovery of a Novel Dual Inhibitor Targeting Tubulin and Histone Deacetylase 8 for Treatment of the Ovarian Cancer. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01002

BibTeX
@article{Cai2026,
  author = {Cai, Shaowen and Shi, Furui and Chen, Jiayi and Yu, Min and Shi, Zhixian and Tang, Hairong and Wang, Yang},
  title = {Discovery of a Novel Dual Inhibitor Targeting Tubulin and Histone Deacetylase 8 for Treatment of the Ovarian Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01002}
}
Kostenlos starten →